Journal
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 48, Issue 5, Pages 931-938Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2006.04.090
Keywords
-
Categories
Ask authors/readers for more resources
OBJECTIVES We sought to compare the antiplatelet effects of three clopidogrel loading doses (LDs). BACKGROUND Administration of a 300-mg clopidogrel. LID is beneficial in situations requiring rapid platelet inhibition. Whether higher LDs can provide further benefits remains unknown. METHODS Patients (n = 103) with non-ST-segment elevation acute coronary syndromes were randomized to receive a 300-mg, 600-mg, or 900-mg clopidogrel LD, given on top of other standard therapy (including acetylsalicylic acid). The main outcome measure was inhibition of adenosine diphosphate-induced inhibition of platelet aggregation (IPA); inhibition of platelet activation, inflammatory markers, troponin I release, and major adverse cardiac events also were evaluated; all measures were blindly evaluated. RESULTS Compared with the 300-mg LD, greater doses were associated with significantly greater platelet inhibition, with dose-effect relationships observed for onset of action, maximal plateau, 24-h areas under the curves of IPA, and rates of low IPA (< 10% at 6 h), using 20 mu mol/1 major adverse cardiac events. A significant dose-response was also observed for the vasodilator-stimulated phosphoprotein index, a measure of P2Y(12) receptor inhibition. Similar but nonsignificant trends were observed for troponin release and major adverse cardiac events. Bleeding rates were similar in each group. CONCLUSIONS In low-to-moderate risk patients with non-ST-elevation acute coronary syndromes, clopidogrel LDs > 300 mg provide a faster onset of action, a higher IPA plateau, and greater reductions in platelet activation during the first 24 h. A 900-mg LID may induce a greater antiplatelet effect than 600 mg, when compared with the standard 300-mg regimen. These findings require further clinical confirmation.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available